Skip to Main Content

Bahman Jabbari, MD

Professor Emeritus of Neurology
DownloadHi-Res Photo

About

Titles

Professor Emeritus of Neurology

Biography

Dr. Jabbari is a Professor Emeritus of Neurology. Dr. Jabbari's clinical interests include: Parkinson's disease; pharmacologic treatment and DBS treatment, clinical research Movement disorders; restless legs syndrome, spinocerebellar ataxias/degenerations, gait disorders, dystonias, tremors, Huntington's disease, Tourette syndrome and tardive dyskinesias, treatment of refractory medical and neurological disorders with botulinum toxins; chronic migraine , tardive dyskinesias, spasticity related to stroke, multiple sclerosis, cerebral palsy, focal pain syndromes ( postherpetic or posttraumatic neuralgia, planar faciitis, low back pain, myofacila pain syndrome)

  • Born in Rasht, Iran in 1941
  • Residency in Neurology : Albany , NY 1969-1972
  • Felloship : EEG/EMG : Tulane university 1972-1973
  • Staff Tulane university : New Orleans, LA 1973-1976
  • Staff-Walter Reed Medical Center : Washington DC 1976-1997
  • Chairman Department of Neurology: Uniformed services University, Maryland 1997-2004
  • Chief, division of Pakinson's disease and Movement disorders : Yale University: 2004 to 2014
  • Director, botulinum toxin treatment program : Yale University : 2008 to 2015

Appointments

Other Departments & Organizations

Education & Training

Fellow
Tulane University School of Medicine (1973)
Resident
Albany Medical Center (1972)
MD
Tehran University (1966)

Board Certifications

  • Neurology

    Certification Organization
    AB of Psychiatry & Neurology
    Original Certification Date
    1976

Research

Overview

My scientific interest in botulinum neurotoxin research is based on the wide range of synaptic mechanisms through which these toxins exert their functions. Since botulinum toxins also inhibit the release of acetylcholine from presynaptic vesicles, they can improve hyperkinetic disorders. This is the basis for studying the effect of incobotulinum toxin-A (Xeomin) in Parkinsonian and essential tremor. Previous studies of botulinum toxin A have demonstrated the efficacy of intramuscular onabotulinum toxin A in reducing the tremor of essential tremor, but the results were confounded by development of finger weakness in 30% of these patients. Our current protocols apply a customized pattern of injection (rather than fixed injection) and smaller doses given to more muscles under EMG guidance. This approach will hopefully avoid muscle weakness. In restless legs syndrome, foot movements are dorsiflexion/plantar flexion. Our restless legs syndrome protocol explores the effect of incobotulinum toxin-A by injecting xeomin into gastrocnemius and tibialis anterior muscles. One of our other major areas of interest is in pain research, as both type A and B toxins inhibit the release of pain modulators (substance P, calcitonin gene related peptide, glutamate and bradykinin) from presynaptic vesicles. Two of our current protocols assess the efficacy of incobotulinum toxin-A (Xeomin) in low back pain and abobotulinum toxin-A on post-radiation and post-surgical pain.

We are involved in several protocols involving patients with movement disorders:

1. Evaluation of efficacy of botulinum toxin-A (Xeomin) in Parkinsonian tremor (PI: Jabbari)

This is a double blind, parallel design, randomized study of adult patients with Parkinson’s resting tremor, which involves xeomin injection into forearm and hand muscles under EMG guidance.

2. Evaluation of efficacy of botulinum toxin-A (Xeomin) in treatment of restless legs syndrome (PI: Jabbari)

This is a double blind, randomized, cross over study of adult patients with restless legs syndrome. Xeomin is injected into the tibialis anterior and gastrocnemius muscles.

3. Evaluation of efficacy of botulinum toxin-A (Xeomin) in essential tremor (PI: Machado and co-PI: Jabbari)

This is a double blind, parallel design, randomized study of adult patients with essential tremor in which xeomin is injected into forearm and hand muscles under EMG guidance

4. A phase II, multi-center, open label, study to evaluate the efficacy and safety of WTX101 (a new copper depleter) in adult patients with Wilson’s Disease (PI: Schiltsky and co-PI: Jabbari)

see research description

Medical Subject Headings (MeSH)

Botulinum Toxins; Deep Brain Stimulation; Dyskinesias; Dystonia; Electrophysiology; Movement Disorders; Muscle Spasticity; Neurology; Parkinson Disease; Tremor

Research at a Glance

Yale Co-Authors

Frequent collaborators of Bahman Jabbari's published research.

Publications

2024

2023

2022

2020

2018

Academic Achievements & Community Involvement

  • honor

    Instructor of the year

  • honor

    US Army Meritorious service medal

  • honor

    Membership American Neurological Association

  • honor

    United States Army "A" designee

  • honor

    Superior performance Award

Get In Touch

Contacts

Academic Office Number
Appointment Number
Office Fax Number
Clinic Fax Number

Administrative Support